Research is ongoing to expand the use of PARP inhibitors beyond BRCA-mutated cancers. Studies are exploring their efficacy in combination with other treatments such as immunotherapy and chemotherapy. There is also interest in identifying additional biomarkers beyond BRCA mutations to better select patients who may benefit from PARP inhibition.
